Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stephan Quentzel

Psychiatry New York City, NY Medical Doctor

NPI 1699817080 CMS profile 76628

10 Union Square East, Suite 2B, Beth Israel Hospital - Phillips Ambulatory Care Center, New York City, NY 10003

Open in the dashboard

General payments

$137,953

419 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stephan Quentzel of New York City, NY is reported in the CMS Open Payments database as having received $137,953 across 419 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,718 43
2024 General $15,102 50
2023 General $27,404 56
2022 General $42,289 100
2021 General $25,083 68
2020 General $6,736 29
2019 General $14,622 73

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephan Quentzel
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Stephan Quentzel were reported at $6,718. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Stephan Quentzel Psychiatry median Middle half National median
2019 $14,622 $184 $59–$605 $163
2020 $6,736 $119 $36–$372 $114
2021 $25,083 $143 $43–$576 $132
2022 $42,289 $153 $50–$590 $149
2023 $27,404 $170 $56–$651 $160
2024 $15,102 $179 $57–$673 $164
2025 $6,718 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alkermes, Inc. $70,861 117 payments
  2. AbbVie, Inc. $42,317 121 payments
  3. Allergan Inc. $17,453 57 payments
  4. Sunovion Pharmaceuticals Inc. $5,117 27 payments
  5. Lundbeck LLC $576 34 payments
  6. Teva Pharmaceuticals USA, Inc. $436 13 payments
  7. Bausch Health US, LLC $389 17 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $137 7 payments
  9. Supernus Pharmaceuticals, Inc. $125 5 payments
  10. ITI, Inc. $118 4 payments
  11. Other $424 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $122,260 55 payments
  2. Food and Beverage $8,053 262 payments
  3. Travel and Lodging $7,527 100 payments
  4. Education $113 2 payments
Products named General payments · program years 2019–2025
  1. LYBALVI Cns $70,861 117 payments
  2. LYBALVI Cns $70,818 115 payments
  3. LYBALVI Cns $70,818 115 payments
  4. LYBALVI Cns $70,818 115 payments
  5. VRAYLAR Neuroscience $37,690 104 payments
  6. VRAYLAR Neuroscience $21,881 73 payments
  7. LATUDA $5,117 27 payments
  8. REXULTI $462 26 payments
  9. APLENZIN $389 17 payments
  10. WELLBUTRIN $344 14 payments
  11. Other $1,589 61 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

186

Median for Psychiatry & Neurology: 100

Drug cost

$4,006

Median for Psychiatry & Neurology: $2,986

Branded share of claims

14.5%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Bupropion Xl Bupropion Hcl Brand 27 $1,197
Duloxetine Hcl Generic 16 $878
Aripiprazole Generic 16 $822
Mirtazapine Generic 15 $238
Gabapentin Generic 18 $225
Trazodone Hcl Generic 17 $214
Zolpidem Tartrate Generic 25 $108
Clonazepam Generic 11 $107
Fluoxetine Hcl Generic 15 $103
Diazepam Generic 11 $66

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LYBALVI
  • Alkermes, Inc. $10,237
$10,237 — —
VRAYLAR
  • AbbVie, Inc. $4,249
$4,249 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $119
$119 — —
REXULTI
  • Lundbeck LLC $73
  • Otsuka America Pharmaceutical, Inc. $27
$100 — —
APLENZIN
  • Bausch Health US, LLC $84
$84 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

419 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record